Cash-Starved Biotech Secures Up to $10M Debt Facility to Finish Alopecia Trial
HCWB is trading near its 52-week low of $1.08 (7.4% above the low).
Summary
HCW Biologics closed a debt financing on November 4 that puts $3.0 million in the door immediately, with another $7.0 million available subject to conditions — up to $10.0 million total. That is a lifeline for a company that reported only $741,324 in cash at Q2 and warned in August of substantial doubt about its ability to continue as a going concern. The stated use is to finish the dose-escalating Phase 1 study of HCW9302 in alopecia areata and set the Recommended Phase 2 Dose, which the company expects in the first quarter of 2027. The $7.0 million tranche is conditional, so the full amount is not guaranteed; the $3.0 million at close is what's certain. This follows a string of dilutive raises — a $1.5M private placement in September and resale registrations for Armistice Capital shares in August and October — so the shift to debt avoids immediate further equity dilution. Watch the Q1 2027 HCW9302 readout, which this funding is meant to reach.
At the time of this announcement, HCWB was trading at $1.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.4M. The 52-week trading range was $1.08 to $23.94. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.